118 related articles for article (PubMed ID: 8292816)
1. Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice.
Ashizawa T; Asada M; Kobayashi E; Okabe M; Gomi K; Hirata T
Anticancer Drugs; 1993 Oct; 4(5):577-83. PubMed ID: 8292816
[TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture.
Gomi K; Ohno H; Nomura K; Okabe M; Kobayashi K; Niitani H
Jpn J Cancer Res; 1992 May; 83(5):532-9. PubMed ID: 1618703
[TBL] [Abstract][Full Text] [Related]
3. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
[TBL] [Abstract][Full Text] [Related]
4. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
[TBL] [Abstract][Full Text] [Related]
5. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
6. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
Soria JC; Brisgand D; Le Chevalier T
Ann Oncol; 2001 Dec; 12(12):1667-70. PubMed ID: 11843242
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice.
Tsuruo T; Inaba M; Tashiro T; Yamori T; Ohnishi Y; Ashizawa T; Sakai T; Kobayashi S; Gomi K
Anticancer Drugs; 1994 Dec; 5(6):634-40. PubMed ID: 7888700
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
Evans WK; Le Chevalier T
Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells.
Knick VC; Eberwein DJ; Miller CG
J Natl Cancer Inst; 1995 Jul; 87(14):1072-7. PubMed ID: 7616599
[TBL] [Abstract][Full Text] [Related]
11. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
Zhu K; Fang W; Chen Y; Lin S; Chen X
Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
[TBL] [Abstract][Full Text] [Related]
13. [A randomized study of navelbine compared to navelbine and cisplatin compared to vindesine and cisplatin in the treatment of inoperable non-small-cell lung carcinoma. The results of a European multicenter study including 612 patients].
González Larriba JL; Alberola V; Lianes P; Panizo A; Carrato A; Muñoz Quintana A; Cardenal F; Gracia JM; Moyano A; Díaz-Rubio E
Rev Clin Esp; 1994 Nov; 194(11):953-9. PubMed ID: 7846351
[TBL] [Abstract][Full Text] [Related]
14. Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine.
Otter GM; Sirotnak FM
Cancer Chemother Pharmacol; 1994; 33(4):286-90. PubMed ID: 8281620
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
[TBL] [Abstract][Full Text] [Related]
16. [Navelbine plus cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 42 cases].
Zhang X; Sun Y; Kong W
Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):60-2. PubMed ID: 10921062
[TBL] [Abstract][Full Text] [Related]
17. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial.
Depierre A; Chastang C; Quoix E; Lebeau B; Blanchon F; Paillot N; Lemarie E; Milleron B; Moro D; Clavier J
Ann Oncol; 1994 Jan; 5(1):37-42. PubMed ID: 8172790
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor activity of navelbine (vinorelbine ditartrate), a new vinca alkaloid analog].
Ashizawa T; Miyoshi K; Asada M; Kobayashi E; Okabe M; Morimoto M; Gomi K; Hirata T
Gan To Kagaku Ryoho; 1993 Jan; 20(1):59-66. PubMed ID: 8422187
[TBL] [Abstract][Full Text] [Related]
19. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer.
Le Chevalier T; Brisgand D; Soria JC; Douillard JY; Pujol JL; Ruffie P; Aberola V; Cigolari S
Oncologist; 2001; 6 Suppl 1():8-11. PubMed ID: 11181998
[TBL] [Abstract][Full Text] [Related]
20. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.
Berthelot JM; Will BP; Evans WK; Coyle D; Earle CC; Bordeleau L
J Natl Cancer Inst; 2000 Aug; 92(16):1321-9. PubMed ID: 10944554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
